There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR) and Calliditas Therapeutics (CALT) with bullish sentiments.
Arrowhead Pharmaceuticals (ARWR)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Arrowhead Pharmaceuticals, with a price target of $106.00. The company’s shares closed last Wednesday at $75.43.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 29.6% and a 54.9% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Madrigal Pharmaceuticals, and Frequency Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $99.50 average price target.
See today’s analyst top recommended stocks >>
Calliditas Therapeutics (CALT)
In a report released today, Edwin Zhang from H.C. Wainwright reiterated a Buy rating on Calliditas Therapeutics, with a price target of $52.00. The company’s shares closed last Wednesday at $31.23.
According to TipRanks.com, Zhang is a 1-star analyst with an average return of -10.0% and a 50.0% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Liminal BioSciences, and FibroGen.
Calliditas Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $48.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
